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A B S T R A C T
Background
Kidney stones affect people worldwide and have a high rate of recurrence even with treatment. Recurrences are particularly prevalent
in people with low urinary citrate levels. These people have a higher incidence of calcium phosphate and calcium oxalate stones. Oral
citrate therapy increases the urinary citrate levels, which in turn binds with calcium and inhibits the crystallisation thus reduces stone
formation. Despite the widespread use of oral citrate therapy for prevention and treatment of calcium oxalate stones, the evidence to
support its clinical efficacy remains uncertain.
Objectives
The objective of this review was to determine the efficacy and adverse events associated with citrate salts for the treatment and prevention
of calcium containing kidney stones.
Search methods
We searched the Cochrane Kidney and Transplant Specialised Register to 29 July 2015 through contact with the Trials’ Search Co-
ordinator using search terms relevant to this review.
Selection criteria
We included randomised controlled trials (RCTs) that assessed the efficacy and adverse events associated with citrate salts for the
treatment and prevention of calcium containing kidney stones in adults treated for a minimum of six months.
Data collection and analysis
Two authors assessed studies for inclusion in this review. Data were extracted according to predetermined criteria. Summary estimates
of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals
(CI) for dichotomous outcomes, and mean difference (MD) and 95% CI for continuous outcomes.
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Main results
We included seven studies that included a total of 477 participants, most of whom had oxalate stones. Of these, three studies (247
participants) compared potassium citrate with placebo or no intervention; three (166 participants) compared potassium-sodium citrate
with no intervention; and one (64 participants) compared potassium-magnesium citrate with placebo. Overall, quality of the reporting
of the included studies was considered moderate to poor, and there was a high risk of attrition bias in two studies.
Compared with placebo or no intervention, citrate therapy significantly reduced the stone size (4 studies, 160 participants: RR 2.35,
95%CI 1.36 to 4.05).New stone formationwas significantly lower with citrate therapy compared to control (7 studies, 324 participants:
RR 0.26, 95% CI 0.10 to 0.68). The beneficial effect on stone size stability was also evident (4 studies, 160 participants: RR 1.97,
95% CI 1.19 to 3.26). Adverse events were reported in four studies, with the main side effects being upper gastrointestinal disturbance
and one patient reported a rash. There were more gastrointestinal adverse events in the citrate group; however this was not significant
(4 studies, 271 participants: RR 2.55, 95% CI 0.71 to 9.16). There were significantly more dropouts due to adverse events with citrate
therapy compared to control (4 studies, 271 participants: RR 4.45, 95% CI 1.28 to 15.50). The need for retreatment was significantly
less with citrate therapy compared to control (2 studies, 157 participants: RR 0.22, 95% CI 0.06 to 0.89).
Authors’ conclusions
Citrate salts prevent new stone formation and reduce further stone growth in patients with residual stones that predominantly contain
oxalate. The quality of reported literature remains moderate to poor; hence a well-designed statistically powered multi-centre RCT is
needed in order to answer relevant questions concerning the efficacy of citrate salts.
P L A I N L A N G U A G E S U M M A R Y
Citrate salts for preventing and treating calcium containing kidney stones in adults
Kidney stones are one of the most common disorders of the urinary tract. They typically affect people aged 40 to 60 years of age and
are twice as common in men than women although recent data suggest the risks are more equal. Calcium stones are the most common
type of kidney stone and occur in two major forms: calcium oxalate and calcium phosphate. Kidney stones can cause severe abdominal
pain and may require urgent treatment; they are one of the main causes of unscheduled admissions in urological practice.
Following treatment even first time stone formers have a risk for recurrence which increased with each subsequent stone. This increased
risk of recurrence of stones is mainly attributed to altered composition of urine i.e. low citrate levels. Various prevention strategies
including increased fluid intake and oral citrate supplements have been tried to modify the chemical composition of the urine. Citrate
therapy is believed to stop crystals from growing into stones. The uncertainty of the true benefit of citrate therapy prompted this review.
We included seven studies (477 participants) in this review. Citrate salts significantly reduce stone size, prevent new stone formation,
and results in stone size stability. People experienced more side effects, such as gastrointestinal disturbance, when using citrate salts than
when using placebo, however the need for retreatment for stone removal was significantly less with citrate therapy.
B A C K G R O U N D
Description of the condition
Kidney stones (renal stone disease) remain a public health problem
around the world irrespective of geographical, cultural or racial
backgrounds, with an incidence of approximately 0.1% to 0.3%.
The lifetime risk is estimated to be between 10% and 20% in
the Western world, but can be as high as 20% to 25% in the
Middle East. Stone disease typically affects men two times more
commonly than women and peak incidence is in the fourth to
sixth decades of life (Magaret 2007; Pak 1998; Sarada 1991). Re-
cent studies reported that the male:female ratio of patients with
stones altered from 1.6:1 to 1.2:1 (Nowfar 2011),1.7:1 to 1.3:1
(Scales 2007). Between the mid-1970s and the mid-1990s, the
prevalence of stone disease increased from 3.2% to 8.8% in the
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USA (Scales 2012; Stamatelou 2003). The stone recurrence rate
without treatment is approximately 10% at one year, 33% at five
years, 50% at 10 years, and 75% at 20 years (Sutherland 1985;
Trinchieri 1999; Uribarri 1989). Following first recurrence, the
subsequent relapse risk is increased with a shortened time interval
between recurrences (Strauss 1982).
Most stones (60% to 80%) are composed of calcium salts (cal-
cium oxalate, calcium phosphate, or both). The remainder are
non-calcium stones such as struvite (5% to 15%), uric acid (5%
to 10%), cystine (1%), or other substances (1%) (Miller 2007).
Kidney stone formation is based on supersaturation of urinary
salts and crystal retention in the urinary tract. Urinary Inhibitors
(citrate, pyrophosphate, magnesium, nephrocalcin) and promot-
ers (cell debris, protein aggregates) are involved in the process and
deficiency of inhibitors or abundance of promoters in the urine
thought to predispose to stone disease (Magaret 2007).
The association of lower urinary citrate with kidney stones was
first reported in 1941 (Kissin 1941). Hypocitraturia has been re-
ported in 15% to 63% of patients with kidney stones, present-
ing either as a single abnormality (10%) or in conjunction with
other metabolic disorders (50%) (Zuckerman 2009). Urinary cit-
rate inhibits the crystallisation of calcium salt, levels of less than
1.67 mmol/day (320 mg/day) is defined as hypocitraturia. Severe
hypocitraturia is citrate excretion of less than 100 mg/day (0.53
mmol/day) and mild to moderate hypocitraturia is citrate excre-
tion of 100 to 320 mg/day (0.53 to 1.67 mmol/day). These stones
are typically composed of calcium phosphate and calcium oxalate.
Most people with hypocitraturia are treated with potassium citrate
to raise urine citrate levels to reduce the risk of recurrent stone
formation.
Minimally invasive techniques including extracorporeal shock
wave lithotripsy (ESWL), percutaneous nephrolithotomy (PCNL)
and flexible ureteroscopy have transformed the management of
stone disease in the last three decades. These newer modalities in-
volve a short hospital stay and, as ESWL can be performed with-
out general anaesthesia, stone treatment, rather than prevention,
has become an attractive option for clinicians. However, these in-
terventions cost more to the health care organisations compared
to preventive strategies. Preventive measures, which are cost ef-
fective, are needed because of the high rate of recurrence (Parks
1996). Metabolic abnormalities are responsible for stone recur-
rence in 89% to 96% of patients (Levy 1995; Weisinger 1995). A
recent study observed a single urine metabolic risk factor in 67%
and multiple factors in 27% of patients (Spivacow 2010). Active
preventive treatment may be helpful in this group therefore it is
desirable to offer specific recurrence preventive measures.
Description of the intervention
Hypocitraturia is recognised as a cause of kidney stone formation.
Evidence from non-randomised studies and the European Asso-
ciation of Urology has recommended treatment of hypocitraturia
(Turk 2014). The incidence of hypocitraturia varies from 20% to
60% in people who have a propensity to form stones (Nicar 1983;
Pak 2003). Hypocitraturia has been observed in 87%, 76% and
40% of people with calcium oxalate, calcium phosphate and uric
acid stones respectively (Ratan 2002). The role of citrate prepara-
tion has been well documented (Fan 2001; Pak 1991; Pak 1994;
Tiselius 1993). Three properties of citrate are considered to help
prevent urinary stone formation: (a) urinary citrate acts as an in-
hibitor of calcium oxalate and calcium phosphate crystal growth
and aggregation; (b) citrate alters the ion-activity products of both
calcium oxalate and phosphate; and (c) intestinal complex forma-
tion between calcium and citrate may reduce calcium excretion.
Citrate taken orally is metabolised to bicarbonate in the liver and
provides an alkaline load.
There are several citrate containing compounds that have been in-
vestigated for the management of stone disease (Allie-Hamdulay
2005; Barcelo 1993; Cicerello 1994; Soygur 2002). The ad-
verse effects of citrate treatment are usually gastrointestinal-re-
lated (Mattle 2005). Various citrate formulations, including potas-
sium citrate (Barcelo 1993; Whalley 1996), sodium-potassium
citrate (Hofbauer 1994), calcium citrate (Levine 1994), calcium-
sodium citrate (Schwille 1997), and potassium-magnesium citrate
(Ettinger 1997) have shown to be effective in the treatment and
prophylaxis of stone disease. Sodium-potassium citrate in combi-
nation with calcium lactate has also been used (Ito 1992).
How the intervention might work
Citrate inhibits the formation of calciumoxalate stones by forming
complexes with urinary calcium thereby reducing urinary calcium
oxalate saturation. Citrate also inhibits the nucleation, growth,
and agglomeration of calcium oxalate crystals (Kok 1986; Meyer
1975).
Why it is important to do this review
Various studies have demonstrated that citrate excretion is signif-
icantly lower in stone formers than in normal controls and cit-
rate supplementation increases the urinary citrate level. A number
of non-randomised studies have demonstrated a beneficial effect
of citrate salts therapy in patients with kidney stones. Preminger
1988 demonstrated superiority of potassium citrate’s over sodium-
potassium citrate. The European Association of Urology Guide-
lines on Urolithiasis (Turk 2014) recommends the use of citrate
in hypocitraturia. However, the evidence base for this recommen-
dation is limited.
There is no consensus on the best formulation to treat recurrent
kidney stone disease. This uncertainty warranted a systematic re-
view to synthesise all available evidence on the efficacy, safety and
acceptability of products containing citrate salts to assist people
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with stone disease and to reduce recurrence by creating good evi-
dence-based treatment decisions.
O B J E C T I V E S
The objective of this review was to determine the efficacy and
adverse events associated with citrate salts for the treatment and
prevention of calcium containing kidney stones.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) that assessed
the efficacy and adverse events associated with citrate salts for the
treatment and prevention of kidney stones.
Types of participants
Inclusion criteria
• Age: patients aged 16 years or older
• Stone characteristics:
◦ Primary or residual kidney stones post ESWL/post
ureteroscopic lithotripsy/PCNL, or
◦ Active stone formers rendered stone-free following
intervention who received citrate therapy for ≥ 6 months.
Exclusion criteria
• Patients with allergies or who are contraindicated to receive
citrate salts
• Pregnant women and children with kidney stones
• Kidney impairment (estimated glomerular filtration rate
(eGFR) < 30 mL/min/1.73m²).
Types of interventions
• Oral citrate therapy administered to treat or prevent kidney
stones and compared to placebo or no intervention.
• We assessed only those interventions that had a minimum
treatment duration of at least six months.
• Studies comparing citrate salts with other pharmacological
interventions for preventing kidney stones were excluded.
Types of outcome measures
Primary outcomes
• Reduction in stone size (reduced residual fragments or
complete disappearance) or reduction in stone recurrence rate
(new stone formation) documented on plain abdominal
radiography or intravenous urography or computerised
tomography (CT) at 6, 12 and 24 months after commencement
of treatment.
• Stability of stone disease documented on plain abdominal
radiography or intravenous urography or CT at 6, 12 and 24
months after commencement of treatment.
Secondary outcomes
• Retreatment rates (retreatment for residual stones)
documented during follow-up
• Correction of urinary levels of stone promoters and
inhibitors (i.e. alterations in the blood and urine metabolic
parameters following treatment)
• Non-compliance with citrate salts
• Serious adverse events and adverse events associated with
the intervention (e.g. citrate-related side effects documented
during and after therapy).
Search methods for identification of studies
Electronic searches
We searched theCochraneKidney andTransplant SpecialisedReg-
ister (to 29 July 2015) through contact with the Trials Search Co-
ordinator using search terms relevant to this review. The Cochrane
Kidney and Transplant Specialised Register contains studies iden-
tified from the following sources.
1. Quarterly searches of the Cochrane Central Register of
Controlled Trials CENTRAL
2. Weekly searches of MEDLINE OVID SP
3. Hand searching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of Cochrane Kidney and Transplant. Details of
these strategies, as well as a list of hand searched journals, confer-
ence proceedings and current awareness alerts, are available in the
Specialised Register section of information about the Cochrane
Kidney and Transplant.
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See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and
clinical practice guidelines.
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
A list of titles and abstracts of potentially relevant clinical stud-
ies were generated by the search strategy and imported in to bib-
liographic software (EndNote®). This list was screened by two
authors independently and fully published papers were retrieved
where appropriate. These papers were further assessed to ensure
they met the inclusion criteria of this review and data extraction.
Disagreements were resolved by consultation with a third author.
We did not impose any language or any other restrictions on any
of these searches. Non-English papers were translated where re-
quired.
Data extraction and management
Data extraction was carried out independently by the two authors
using standard data extraction forms. Studies reported in non-En-
glish language journals were translated before assessment. Where
more than one publication of one study was noted, only the publi-
cation with the most complete data was included. Disagreements
were resolved by consensus or referred to a third author. Quality
of reporting of the studies was completed independently by one
author using the CONSORT 2010 checklist (Schulz 2010). We
contacted two authors (Lojanapiwat 2011; Soygur 2002) by email
for further data, but unfortunately no responses were received.
Assessment of risk of bias in included studies
Risk of bias was independently assessed by two authors using the
risk of bias assessment tool (Higgins 2011) (see Appendix 2). Data
were also assessed according to the method of randomisation, al-
location concealment, adequate descriptions of numbers, and rea-
sons for patient withdrawal, as detailed in the Cochrane Hand-
book for Systematic Review of Interventions (Higgins 2011).
Measures of treatment effect
For dichotomous outcomes (success, effectiveness, re-treatment,
and serious adverse effects) results are expressed as risk ratios (RR)
with 95% confidence intervals (CI). Where continuous scales of
measurement are used to assess the effects of treatment (mean pro-
cedure time), the mean difference (MD) is used, or the standard-
ised mean difference (SMD) if different scales were used.
Unit of analysis issues
The first period of cross-over studies was to be included.
Assessment of heterogeneity
Heterogeneity was analysed using a Chi² test on N-1 degrees of
freedom, with an alpha of 0.05 used for statistical significance and
with the I² test (Higgins 2003). I² values of 25%, 50% and 75%
correspond to low, medium and high levels of heterogeneity.
R E S U L T S
Description of studies
See: Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
Forty reports were retrieved as identified in the Cochrane Kidney
and Transplant Specialised Register and further four reports were
retrieved via a cross-link search. These 44 reports were screened
(titles, abstracts and full-text) and seven studies (eight reports)
fulfilled our inclusion criteria (see Figure 1).
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Figure 1. Flow diagram showing article selection process
Prior to publication of this review a final search of the Specialised
Register identified one new potential study (Krishna Reddy 2014)
and one ongoing study (NCT01754779) and these will be assessed
for inclusion in a future update of this review.
Included studies
The primary objective for all studies (Barcelo 1993; Cicerello
1994; Ettinger 1997; Hofbauer 1994; Jimenez Verdejo 2001;
Lojanapiwat 2011; Soygur 2002) was to demonstrate the efficacy
of citrate salts in reducing the number of stone episodes from
a population of known stone formers. Urinary citrate levels be-
fore and after treatment was a secondary outcome measure in five
studies (Cicerello 1994; Ettinger 1997; Hofbauer 1994; Jimenez
Verdejo 2001; Lojanapiwat 2011).
Design
All studies were RCTs and participants received a minimum of
six months treatment. Three studies had a follow-up period of 12
months (Cicerello 1994; Lojanapiwat 2011; Soygur 2002). Three
studies reported 36 months follow-up (Barcelo 1993; Ettinger
1997; Hofbauer 1994) and one study reported 48 months follow-
up (Jimenez Verdejo 2001).
Sample sizes
These seven studies reported the results for 477 participants. One
hundred and sixty one participants had residual stones < 5 mm
post ESWL/PCNL; the remaining 316 participants were stone-
free at the start of the study but were active stone formers.
Setting
Five studies were conducted at a university teaching hospi-
tal (Ettinger 1997; Hofbauer 1994; Jimenez Verdejo 2001;
Lojanapiwat 2011; Soygur 2002); one study was conducted at a
general hospital with university links (Cicerello 1994) and one
study was conducted at a private hospital with university links
(Barcelo 1993).
Participants
Selection criteria varied among included studies.
• Ettinger 1997 included patients with two or more calculi
within the previous five years and at least one calculus within the
year prior to recruitment.
• Barcelo 1993 selected patients with moderately severe active
urolithiasis (two or more stones formed during the previous two
years composed of calcium oxalate or a mixture of calcium
oxalate and calcium phosphate) with low or low normal urinary
citrate.
• Hofbauer 1994 recruited patients with recurrent idiopathic
calcium oxalate urolithiasis (at least one stone over the previous
three years).
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• Lojanapiwat 2011 studied patients who were stone-free or
had residual stones < 4 mm following ESWL or PCNL.
• Soygur 2002 and Jimenez Verdejo 2001 enrolled post shock
wave lithotripsy (SWL) patients who were either stone-free or
residual stones of < 5 mm or < 2 mm respectively.
• Cicerello 1994 recruited patients with residual fragments <
5 mm post ESWL as well as patients with struvite stones, the
struvite stone patients were excluded from analysis in this review.
Interventions
Three studies used potassium citrate (Barcelo 1993; Jimenez
Verdejo 2001; Soygur 2002), three studies used potassium-sodium
citrate (Cicerello 1994; Hofbauer 1994; Lojanapiwat 2011) and
one study used potassium-magnesiumcitrate (Ettinger 1997) ther-
apy. Dietary advice was given to both placebo and treatment arms
of all the studies. No study made use of the same dosing regimen
and length of follow-up differed between the studies.
Outcomes
Among the seven included RCTs, five (Barcelo 1993; Ettinger
1997; Hofbauer 1994; Lojanapiwat 2011; Soygur 2002) reported
participants’ demographic characteristics; Jimenez Verdejo 2001
did not report any participants’ demographic details. All studies
reported outcomes with regard to new stone formation, and four
studies (Cicerello 1994; JimenezVerdejo 2001; Lojanapiwat 2011;
Soygur 2002) reported on stone stability and reduction in stone
size. Urinary parameters at the end of study were reported by four
studies (Cicerello 1994; Ettinger 1997; Jimenez Verdejo 2001;
Lojanapiwat 2011).
Excluded studies
See: Characteristics of excluded studies.
After initial database search 32 studies (36 reports) which were
found were subsequently considered ineligible. Eight were ex-
cluded because they were not randomised (Jaipakdee 2004; Kato
2004; Khanniazi 1993; Koff 2007; Lee 1999; Pearle 2002;
Preminger 1988; Sakhaee 1983). The remaining 24 studies were
RCTs that investigated interventions for kidney stones that did
not meet our inclusion criteria.
• Three studies (Gao 2010; Sarica 2006a; Schell-Feith 2006)
had patient population age of less than 16 years of age.
• Fourteen studies (Allie-Hamdulay 2005; Aras 2008; Brardi
2012; El-Gamal 2012; He 2004a; Heguilen 2005; Mechlin
2011; Pinheiro 2013; Sakhaee 1983; Schell-Feith 2006; See
2012; Singh 2011a; Tosukhowong 2008; Zerwekh 2007) had
less than six months citrate therapy.
• In four studies (Ettinger 1976; Fernandez Rodriguez 2001;
LIMONE Study 2012; Mortensen 1986) a different intervention
was used. i.e. potassium acid phosphate, thiazide, citric acid.
• Two studies (Premgamone 2001; Singh 2012) citrate was
used in the control group (i.e. no control arm).
• One study (Pak 1992) assessed only biochemical
parameters.
Risk of bias in included studies
In general the risk of bias of the included studies as judged by
the authors was low (Figure 2; Figure 3). However there were
no reported power calculations for sample size in any of the in-
cluded studies. Baseline demographics were reported in all stud-
ies apart from Jimenez Verdejo 2001. Comparison of baseline
demographics was reported by Ettinger 1997. Soygur 2002 and
Cicerello 1994 minimised the patient variables by randomising to
matched groups. The differences in baseline biochemistry between
two groups were reported by Ettinger 1997 as not significant. In
four of the included studies, baseline urinary citrate was compara-
ble (Barcelo 1993; Cicerello 1994; Jimenez Verdejo 2001; Soygur
2002).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Minimisation of confounding variables was ensured by Soygur
2002 and Cicerello 1994 by randomising participants by age, sex
and urinary biochemical markers, no other studies reported how
participant variables were minimised prior to allocation.
Blinding
Two studies were reported as double-blind RCTs (Barcelo 1993;
Ettinger 1997). Ettinger 1997 described blinding of an outcome
assessor who reviewed the X-ray films, andCicerello 1994 reported
the radiologist who reviewed the interval imaging was unaware of
the study protocol.
Incomplete outcome data
In five studies the number of participants randomised matched
the number reported in the results ().
• Barcelo 1993 excluded dropouts from the main analysis but
did report outcomes of five non-compliant participants with
continued follow-up. No interim results were reported for 11
participants who dropped out due to non-compliance.
• Soygur 2002 did not report results in 20/110 participants
who were enrolled in the study, they described randomisation of
90 participants and these are included in the results. They later
report 20 dropouts, of whom six dropped out due to epigastric
discomfort. We have therefore presumed that all 110 were
enrolled and randomised but results for the 90 completing the
study are reported.
• Lojanapiwat 2011 enrolled 80 participants; results were
reported for 76, no explanation was provided about which group
the dropouts belonged to.
Other potential sources of bias
Barcelo 1993 reported a difference in the dosing regimen from
the study protocol dosing regimen. The participants allocated to
the treatment arm were to take 60 mEq/day of potassium citrate
however average consumption was 45 mEq/day and participants
taking less than 30 mEq/day were excluded. Unfortunately the
final results donot specifywhich dosing regimenwasmost effective
in stone prevention.
Effects of interventions
Reduction in stone size
Four studies (Jimenez Verdejo 2001; Lojanapiwat 2011; Soygur
2002; Cicerello 1994) assessed the role of citrate therapy for re-
ducing stone size. Citrate therapy significantly reduced stone size
compared to control (Analysis 1.1 (4 studies, 160 participants):
RR 2.35, 95% CI 1.36 to 4.05; I2 = 4%).
New stone formation
All studies reported new stone formation, with follow-up ranging
from 12 to 48 months. Citrate therapy significantly reduced the
incidence of new stone growth compared to control (Analysis 1.2
(7 studies, 324 participants): RR 0.26, 95% CI 0.10 to 0.68; I
2 = 80%). The high heterogeneity can be attributed to Hofbauer
1994. However when this study was removed from the meta-
analysis there was no change to either the direction or significance
of the result (6 studies, 286 participants): RR 0.24, 95% CI 0.15
to 0.41; I2 = 0%).
Stone size stability
Four studies (Jimenez Verdejo 2001; Lojanapiwat 2011; Soygur
2002; Cicerello 1994) reported stone size stability. Citrate therapy
was significantly beneficial in preventing stone growth compared
to the control group (Analysis 1.3 (4 studies, 160 participants):
RR 1.97, 95% CI 1.19 to 3.26; I2 = 0%).
Urinary citrate levels
Three studies reported urinary citrate levels at the end of the study
(Cicerello 1994; Ettinger 1997; Lojanapiwat 2011). Urinary cit-
rate was significantly higher in the treatment group compared to
the control group (Analysis 1.4 (3 studies, 179 participants): MD
192.77 mg/d, 95% CI 108.19 to 277.35; I2 = 43%). Jimenez
Verdejo 2001 reported urinary citrate levels at the end of study
which were considerably higher than baseline, however standard
deviations were not provided and therefore these results were ex-
cluded from the meta-analysis.
Adverse events
Four studies reported adverse events which included upper gas-
trointestinal disturbance (stomach pains, bloating, nausea) and
rash (Barcelo 1993; Ettinger 1997; Hofbauer 1994; Jimenez
Verdejo 2001). There were more gastrointestinal adverse events in
the citrate group, however this was not significant (Analysis 1.5.1
(4 studies, 271 participants): RR 2.55, 95% CI 0.71 to 9.16; I2
= 45%). Ettinger 1997 reported no significance in rash (Analysis
1.5.2 (64 participants): RR 3.19, 95% CI 0.13 to 75.43). Ettinger
1997 also reported 11.5% of participants complained of diarrhoea
(with one participant reporting multiple episodes), however the
actual number involved was unclear and therefore was excluded
from meta-analysis (Table 1).
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Dropouts
All studies reported dropouts due tonon-compliance. Lojanapiwat
2011 and Soygur 2002 only reported the total number of dropouts
and therefore could not be included in the meta-analysis. There
was no significant difference in dropouts due non-compliance be-
tween citrate therapy and control (Analysis 1.6.1 (5 studies, 311
participants): RR 1.20, 95% CI 0.72 to 1.99; I2 = 0%).
Five studies reported dropouts due to adverse events (Barcelo 1993;
Ettinger 1997; Hofbauer 1994; Jimenez Verdejo 2001; Soygur
2002). Soygur 2002 only reported the total number of dropouts
due to epigastric discomfort (6 participants) and therefore could
not be included in themeta-analysis. Therewere significantlymore
dropouts with citrate therapy compared to control (Analysis 1.6.2
(4 studies, 271 participants): RR 4.45, 95% CI 1.28 to 15.50; I2
= 0%) (Table 1).
Retreatment
Two studies reported the need for retreatment (Barcelo 1993;
Jimenez Verdejo 2001). The need for retreatment was significantly
less with citrate therapy compared to control (Analysis 1.7 (2 stud-
ies, 157 participants): RR 0.22, 95% CI 0.06 to 0.89; I2 = 41%)
(Table 1).
D I S C U S S I O N
Summary of main results
Citrate salts are an effective intervention in the treatment and pre-
vention of kidney stones. The evidence from seven RCTs included
in this review has demonstrated good efficacy with citrate therapy
compared to control (placebo, usual care). However, this review
was unable to demonstrate the most effective type and dose of
citrate salt needed to achieve this clinical benefit. The precise du-
ration of treatment remains to be defined. Interestingly, dropout
rate due to side effects is low.
Overall completeness and applicability of
evidence
We conducted a comprehensive search of the databases and in-
cluded the non-English language literature. Two review authors
independently assessed thematerial tominimise errors, and a third
author was consulted to resolve any disputes. During the initial
part of review process, we excluded the RCT by Cicerello 1994
as it did not meet our inclusion criteria of patients aged 18 year
or more. However, it was felt that this is an important study and
accordingly our initial inclusion criteria was altered to include pa-
tients over 16 years of age. We attempted to contact two authors
for further clarification of datawithout success. The included stud-
ies were assessed for reporting completeness by using the CON-
SORT 2010 checklist (Schulz 2010) however, we took into con-
sideration that six studies were published prior to these guidelines
(Barcelo 1993; Cicerello 1994; Ettinger 1997; Hofbauer 1994;
Jimenez Verdejo 2001; Soygur 2002). The two double-blind stud-
ies (Barcelo 1993; Ettinger 1997) were reported more thoroughly
than the non-blinded studies.
This review included studies reporting on citrate supplements ei-
ther for the treatment or prophylaxis of calcium containing kid-
ney stones. Four studies (Cicerello 1994; Jimenez Verdejo 2001;
Lojanapiwat 2011; Soygur 2002) analysed the effect of citrate salts
in post-treatment group (either post-ESWL or post-PCNL) with
residual stones and were able to demonstrate a significant benefit
of citrate therapy in stone size reduction and stone size stability.
Overall, evidence for specific citrate treatment is limited due to
use of different citrate salts at varying dosage, varying follow-up
periods, and varying follow-up imaging protocols. Despite signif-
icant benefit of citrate salts in prevention and treatment of kidney
stones these limitations, make it difficult to recommend a specific
salt in day-to-day practice.
Quality of the evidence
The seven RCTs included in this review have used different citrate
salts at varying doses. Length of follow-up also varied between the
studies. Power calculations have not been reported by any of the
studies. Barcelo 1993 andEttinger 1997 are double-blind and have
a good description of blinding; however the overall description of
study methodology by Barcelo 1993 was poor as assessed by the
CONSORT 2010 checklist (Schulz 2010). The level of hetero-
geneity reported for outcomes assessing treatment of stone disease
was low, but this was not the case when analysis was carried out
on new stone formation where the level was high: I² = 80%, and
was attributed to Hofbauer 1994. A moderate-strength evidence
(RR, 0.25, 95% CI 0.14 to 0.44) was observed in a recent review
(Fink 2012).
Studies with over 12 months follow-up took serial X-rays at six-
monthly intervals (Barcelo 1993; Ettinger 1997; Hofbauer 1994;
Jimenez Verdejo 2001). Interestingly, the individual data for stone
growth or new stone formation at various intervals has not been
reported in any of the studies. It is therefore impossible to com-
ment on the exact time where change in the stone size did oc-
cur and hence optimal duration of therapy cannot be defined. In
three studies (Cicerello 1994; Lojanapiwat 2011; Soygur 2002)
with up to 12 months follow-up, new stone formation varied from
0% to 8% in the treatment arm and 29% to 42% in the control
arm. Among studies that reported > 12months follow-up (Barcelo
1993; Ettinger 1997; Hofbauer 1994; Jimenez Verdejo 2001), the
percentage of patients with new stones varied from 8% to 69%
in the treatment arm and 44% to 73% in the control arm. Inter-
estingly, Hofbauer 1994 was the only study that failed to demon-
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strate any difference in new stone formation between treatment
and control arms. this study utilised a method of altering the dose
of citrate to maintain urine pH at 7.2. This was considerably more
alkaline than reported by the other studies which reported pH
of 6.29 to 6.64. Eleven of 16 participants in the treatment arm
reported new stone formation; only one of these was reported as a
calcium phosphate stone. Authors failed to report on the number
of stones analysed in the laboratory, therefore, it could be pos-
tulated that the high pH may have attributed to more calcium
phosphate stone formation although the crystal inhibitory effect
of citrate due to the presence of high citrate levels in the urine
should counterbalance the pH effect on calcium phosphate satu-
ration. Another explanation could be the higher intake of sodium
increased calcium excretion and therefore promoted new stone
formation.
Potential biases in the review process
The quality of the included RCTs was moderate to poor which
can reduce the reliability of the estimates of the effectiveness of
citrate salts. We attempted to improve reliability by contacting
two authors for missing data however we were unsuccessful in
obtaining any further details.
Agreements and disagreements with other
studies or reviews
Fink 2012 produced a comprehensive systematic review on the
medical management to prevent recurrent nephrolithiasis this in-
cluded the use of citrate salts. Their findings compliment ours.
Pearle 1999 described the use of citrate salts in a meta-analysis on
treatment options for calcium oxalate stones. There was insuffi-
cient evidence at the time to analyse the effects of this treatment
and reported insufficient evidence.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Citrate salts are currently in use for the treatment and prevention
of calcium-containing kidney stones, this review has highlighted
the evidence that there is some beneficial effect of prescribing this
medicine particularly to prevent new stone formation. The ad-
ministration of citrate salts has been shown to increase excretion of
citrate in the urine. Which citrate salt is most favourable remains
an unanswered question. While there were more adverse events re-
ported with citrate therapy, this was not significant. These findings
must be considered in the context of moderate to poor study de-
sign and incomplete outcome reporting. Consideration also needs
to be made to the economic value of prescribing citrate salts in the
long-term; this is one area which has not been addressed.
Implications for research
This review highlights the lack of good quality reported literature
in the use of citrate salts for kidney stone management. A multi-
centre study which compares different citrate salts in patients who
are stone-free, recurrent stone formers or have residual fragments
< 4 mm to placebo is required. The primary outcomes should be
new stone formation, stone growth, visits to the emergency depart-
ment, proven renal colic or intervention for stones. Alterations in
the urinary parameters should be included as secondary outcomes.
A complete metabolic work up according to European guidelines
at baseline, and six monthly thereafter should be considered. Gold
standard CTKUB should be used for assessment allowing all types
of stones to be studied. The study should incorporate interval re-
porting at 6, 12 and 24 months so evidence can be gathered on
the long term benefits of using citrate salts. Adverse events should
be reported thoroughly and specify if patients dropped out due to
an event. Future studies should report on the health economics of
citrate salts in preventing new stone formation after interventions
(ESWL, PCNL and ureteroscopy) and their impact on the growth
of residual fragments.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barcelo 1993
Methods • Study design: double-blind parallel RCT
• Study duration: 3 years
• Duration of follow-up: 3 years
Participants • Country: Spain
• Setting: single centre (private hospital with university link)
• Adults with severe active lithiasis (2 or more stones formed during the previous 2
years prior to recruitment) composed of calcium oxalate or a mixture of calcium
oxalate and calcium phosphate with an isolated hypocitraturia abnormality
◦ Baseline pH: treatment group (5.4 ± 0.5); control group (not reported)
◦ Baseline citrate (nmol/d): treatment group (1.9 ± 0.5); control group (not
reported)
◦ Baseline calcium (mg/d): not reported
• Number (randomised/analysed): treatment group (28/18); control group (29/20)
• Mean age ± SD: 44 ± 11 years
• Sex (M/F): treatment group (8/10); control group (9/11)
• Exclusion criteria: hypercalciuria; hyperuricosuria; hyperoxaluria; diabetes; kidney
failure; hyperkalaemia; active UTI; gastrointestinal disease; patients with three or more
stones in the same kidney
Interventions Treatment group
• Potassium citrate: 20 mEq (4 tablets) 3 times/d
Control group
• Identical placebo: 4 tablets 3 times/d
Both groups advised to increase fluid intake to 2 to 3 L/d plus reduce sodium intake
Outcomes Outcome measures
• X-ray, blood and urine analyses were taken at baseline and 6 monthly intervals
Outcome definitions
• Stone growth represented an increase of more than 100% in stone size as seen on
the X-ray
• New stone formation represented spontaneous passage in the absence of pre-
existing stones, stone passage without any change in the number of stones, appearance
of new stones on the X-ray or newly formed stones requiring ESWL or surgical removal
Notes • Average tablet consumption was 9/d, non-compliance set at tablet consumption
of ≤ 6 tablets/d
• End of treatment citrate not reported for control group
• Dropouts excluded from study analysis
• Funding: Ferrer Pharma International S.A. Barcelona Spain supplied the
potassium citrate and placebo
Risk of bias
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Barcelo 1993 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly allocated into two
groups
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigators blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Pre-specified outcomes (of interest to this
review) were reported
Other bias Unclear risk Average tablet consumptionwas 9/d, no ev-
idence of the range, those < 6were excluded
Cicerello 1994
Methods • Study design: parallel RCT
• Study duration: 12 months
• Duration of follow-up: 12 months
Participants • Setting: Private hospital with university link
• Country: Italy
• Adults with 2 to 5 residual stones none more than 5 mm on X-ray 6 weeks after
ESWL; calcium oxalate stones (40); stones with infection (30)
◦ Baseline pH: not reported
◦ Baseline citrate (mg/d): treatment group (408.1 ± 137.5); control group
(415.3 ± 160.8)
◦ Baseline calcium (mg/d): treatment group (194.6 ± 108.7); control group
(198.3 ± 91.3)
• Number (randomised/analysed): treatment group (20/20); control group (20/19)
• Mean age ± SD: 42 ± 17 years
• Gender: Male 37; females 33
• Exclusion criteria: > 5 stones and stone size > 5 mm
Interventions Treatment group
• Sodium-potassium citrate: 6 to 8 g/d in 3 divided doses for 12 months
• Advised fluid intake to achieve a daily urine output of more than 2.5 L and to
avoid dietary excess
• The infective stone formers were given full dose antibiotics for 10 d/mo
Control group
• Advised fluid intake to achieve a daily urine output of more than 2.5 L and to
avoid dietary excess
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Cicerello 1994 (Continued)
• The infective stone formers were given full dose antibiotics for 10 d/mo
Outcomes • X-ray: 6 and 12 months
• Kidney ultrasound
• Urine culture and sensitivity
• 24 h urine calcium, sodium, potassium
• Excretory urography at 12 months
• Citrate level in urine
• Urine pH
Outcome definitions
• Stone clearance, stone growth, stone re-aggregation
Notes • Infective stone formers were excluded from this review
• Dropouts excluded from study analysis
• Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but outcome unlikely to be
influenced by blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Pre-specified outcomes (of interest to this
review) were reported
Other bias Low risk The study appears to be free from other
sources of bias
Ettinger 1997
Methods • Study design: double-blind parallel RCT
• Study duration: 36 months
• Duration of follow-up: 37 months
Participants • Country: USA
• Setting: university teaching hospital
• Adults with calculi containing at least 50% or more calcium oxalate; two or more
calculi within 5 years and 1 calculus within past 2 years; no secondary cause for
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Ettinger 1997 (Continued)
nephrolithiasis
◦ Baseline pH: treatment group (6.01 ± 0.46); control group (5.96 ± 0.41)
◦ Baseline citrate (mg/d): treatment group (587 ± 374); control group (549 ±
280)
◦ Baseline calcium (mg/d): treatment group (237 ± 120); control group (275 ±
131)
• Number: treatment group (31); control group (33)
• Mean age ± SD (years): treatment group (48.6 ± 11); control group (47.5 ± 9)
• Sex (M/F): treatment group (22/9); control group (28/5)
• Exclusion criteria: obstructive uropathy; chronic urosepsis; kidney failure (Cr 1.8
mg/dL or more); RTA; ESWL within last six months
Interventions Treatment group
• 42 mEq potassium, 21 mEq magnesium and 63 mEq citrate per day. Divided into
2 tablets 3 times/d for 36 months
Control group:
• Two placebo tablets 3 times/d for 36 months
Both groups: dietary advice: restricted salt, refined sugar, oxalate rich foods, animal
protein but allowed up to two servings of dairy food/d
Outcomes • Coned view of X-ray of kidneys at baseline,12, 24, 36 months
• 24 h urine metabolic screening (SMA-24) at baseline, 5, 9, 13, 17, 21, 25, 29, 33,
37 months
Outcome definitions
• Stone clearance and radiographic appearance of new calculi, or passage of new
stones
Notes • Dropouts excluded from study analysis
• Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Patients were stratified according to pres-
ence of stone or stone-free status and both
groups received visually identical tablets
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
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Ettinger 1997 (Continued)
Selective reporting (reporting bias) Low risk Pre-specified outcomes (of interest to this
review) were reported
Other bias Low risk The study appears to be free from other
sources of bias
Hofbauer 1994
Methods • Study design: parallel RCT
• Study duration: 36 months
• Duration of follow-up: 36 months
Participants • Country: Austria
• Setting: University teaching hospital
• Active stone formers with at least 1 stone annually over previous 3 years
◦ Baseline pH: not reported
◦ Baseline hypocitraturia: treatment group (18/25); control group (16/25)
◦ Baseline hypercalciuria: treatment group (12/25); control group (10/25)
• Number: treatment group (25); control group (25)
• Mean age ± SD (years): treatment group (55 ± 11.2); control group (54.8 ± 14.7)
• Sex (M/F): treatment group (15/10); control group (16/9)
• Exclusion criteria: primary hyperparathyroidism; RTA (type 1); UTI;
hypercalcaemia or diseases of the gastrointestinal tract
Interventions Treatment group
• Sodium-potassium citrate initially 10 g, 3 times/d thereafter individually adapted
to obtain a mean urinary pH of 7.0 to 7.2
Control group
• General prophylactic instructions i.e. abundant liquid intake and dietary
restrictions
Outcomes • X-ray and kidney USS of kidneys at 6-monthly intervals
• 24 h urine collections and serum monitoring 6-monthly
Outcome definitions
• New stone formation
Notes • Dropouts excluded from study analysis
• Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly divided into
two groups
Allocation concealment (selection bias) Unclear risk Not reported
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Hofbauer 1994 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but outcome unlikely to be
influenced by blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Large number of dropouts especially in the
treatment group (36%)
Selective reporting (reporting bias) Low risk Pre-specified outcomes (of interest to this
review) were reported
Other bias Unclear risk Insufficient information to permit judge-
ment
Jimenez Verdejo 2001
Methods • Study design: parallel RCT
• Study duration: 48 months
• Duration of follow-up: 48 months
Participants • Country: Spain
• Setting: university teaching hospital
• Adults post ESWL with calcium oxalate or calcium phosphate stones, those with
residual stones were ≤ 2 mm
◦ Baseline pH: treatment group (5.97); control group (6.01)
◦ Baseline citrate (mg/d): treatment group (548.3); control group (539.4)
◦ Baseline calcium (mg/d): treatment group (206.2); control group (253.4)
• Number (without stones/with residual stones): treatment group (25/25); control
group (25/25)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: metabolic disease, recurrent UTI, Cr ≥1.5 mg/dL; congestive
heart failure; hyperkalaemia; metabolic alkalosis; active gastroduodenal ulcer; intestinal
obstruction; pregnancy or lactation; treatment with diuretics, captopril, indomethacin;
baking sodium or other preparations containing potassium and thiazide or allopurinol
treatment
Interventions Treatment group
• Potassium citrate 40 mEq/d in granular form, divided into two doses
Control group
• General advice of high fluid intake
Outcomes • X-ray at baseline three and six months then six monthly thereafter
Outcome definitions
• Change in residual stone size, new stone formation
Notes • Funding: not reported
Risk of bias
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Jimenez Verdejo 2001 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised into groups
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Not blinded but outcome unlikely to be
influenced by blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Pre-specified outcomes (of interest to this
review) were reported
Other bias Unclear risk Insufficient information to permit judge-
ment
Lojanapiwat 2011
Methods • Study design: parallel RCT
• Study duration: 12 months
• Duration of follow-up: 12 months
Participants • Country: Thailand
• Setting: university teaching hospital
• Kidney stones ≤ 4 mm at 8 weeks after ESWL/PCNL; all patients had calcium
stones on infrared spectroscopy
◦ Baseline pH: treatment group (5.8 ± 0.77); control group (5.7 ± 0.66)
◦ Baseline citrate (mg/d): treatment group (259.2 ± 214.7); control group
(304.3 ± 233.8)
◦ Baseline hypocitraturia: treatment group (4/39); control group (7/37)
• Number (stone-free/residual stones): treatment group (13/26); control group (26/
11)
• Mean age ± SD (stone-free/residual stones): treatment group (48.8 ± 8.26/49.1 ±
12.04); control group (54.1 ± 10.12/45.9 ± 8.93)
• Sex (M/F): treatment group (26/13); control group (26/11)
• Exclusion criteria: UTI; anatomical abnormality; clinical history of urological
surgery
Interventions Treatment group
• Potassium-sodium citrate: 81 mEq/d (27 mEq, 3 times/d).
• Dietary advice to have high fluid intake throughout the study.
Control group
• Dietary advice to have high fluid intake throughout the study
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Lojanapiwat 2011 (Continued)
Outcomes • X-ray at baseline and 12 months
• Serum chemistry and urinalysis at six and 12 months
• Evidence of spontaneous stone passage
Outcome definitions
• New stones determined by spontaneous passage in absence of pre-existing stones
and/or appearance of new stones on X-ray
Notes • Contacted author via email for further clarification of results, no reply obtained
• Dropouts excluded from study analysis
• Funding: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independently block randomised
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding but outcome unlikely to be
influenced by blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Pre-specified outcomes (of interest to this
review) were reported
Other bias Unclear risk Insufficient information to permit judge-
ment
Soygur 2002
Methods • Study design: parallel RCT
• Study duration: 12 months
• Duration of follow-up: 12 months
Participants • Country: Turkey
• Setting: university teaching hospital
• Kidney stones < 5 mm on abdominal X-ray/USS 4 weeks after ESWL; all patients
had calcium oxalate stones without infection
◦ Baseline pH: not reported
◦ Baseline hypocitraturia: treatment group (20/46); control group (14/44)
◦ Baseline hypercalciuria: treatment group (6/46); control group (12/44)
• Number (stone-free/residual fragment): treatment group (28/18); control group
(28/16)
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Soygur 2002 (Continued)
• Mean age, years (stone-free/residual fragment): treatment group (44.6/40.6);
control group (37.2/42.5)
• Sex (M/F): treatment group (32/14); control group (16/30)
• Exclusion criteria: UTI; anatomic abnormality of urinary tract; history of urologic
surgery or urolithiasis; definite metabolic disease (hyperparathyroidism or RTA)
Interventions Treatment group
• Potassium citrate: 60 mEq/d divided into 3 doses
• Dietary advice: high fluid intake to achieve a urine output of 2 L/d, avoid oxalate
foods and restriction of meat products to 8 oz/d
Control group
• Dietary advice: high fluid intake to achieve a urine output of 2 L/d, avoid oxalate
foods and restriction of meat products to 8 oz/d
Outcomes • X-ray and USS of kidneys at 12 months
• Urine citrate levels at 12 months
Outcome definitions
• New stone formation
• Stone growth defined as increment of > 2 mm on X-ray
Notes • Contacted author via email for further clarification of results, no reply obtained
• End of study hypocitraturia not reported for control group.
• End of study hypercalciuria not reported for either treatment of control group
• Dropouts excluded from study analysis
• Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independently block randomised
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Not blinded but outcome unlikely to be
influenced by blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 110 participants were enrolled onto the
study but only 90 randomised - no baseline
data given for those not randomised
Selective reporting (reporting bias) Low risk Pre-specified outcomes (of interest to this
review) were reported
Other bias Unclear risk Insufficient information to permit judge-
ment
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Cr- creatinine; ESWL - extracorporeal shock wave lithotripsy; M/F - male/female; PCNL - percutaneous nephrolithotomy; RCT -
randomised controlled trial; RTA - renal tubular acidosis; USS - ultrasound scan; UTI - urinary tract infection
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allie-Hamdulay 2005 RCT; treatment only for 7 days; no follow-up imaging
Aras 2008 RCT; treatment only for 3 months; no follow-up imaging
Brardi 2012 RCT; treatment only for 5 months.
El-Gamal 2012 RCT; for ureteral calculi and only 4 weeks of treatment
Ettinger 1976 RCT; wrong intervention (potassium acid phosphate)
Fernandez Rodriguez 2001 RCT; wrong intervention (thiazide therapy)
Gao 2010 RCT in children; no follow-up imaging
He 2004a RCT; only 4 weeks of treatment; no radiology
Heguilen 2005 RCT; treatment only for 45 days; no follow-up imaging
Jaipakdee 2004 Non-RCT
Kato 2004 Non-RCT
Khanniazi 1993 Non-RCT
Koff 2007 Non-RCT
Lee 1999 Non-RCT
LIMONE Study 2012 RCT; wrong intervention (citric acid rather than citrate salts)
Mechlin 2011 RCT; stone recurrence was not an outcome; treatment for 3 days; no follow-up imaging
Mortensen 1986 RCT; wrong intervention (thiazide treatment)
Pak 1992 RCT; only biochemical parameter outcomes
Pearle 2002 Non-RCT
Pinheiro 2013 RCT; only 3 days of treatment
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(Continued)
Premgamone 2001 RCT; citrate as control no placebo arm
Preminger 1988 Non-RCT
Sakhaee 1983 RCT; healthy post-menopausal women, treatment for 2 weeks
Sakhaee 2004 Non-RCT
Sarica 2006a RCT in children
Schell-Feith 2006 RCT in neonates; less than 6 months treatment
See 2012 RCT; treatment only for 6 weeks
Singh 2010 RCT; citrate as control no placebo arm
Singh 2011a RCT; treatment only for 12 weeks
Singh 2012 RCT; citrate as control no placebo arm
Tosukhowong 2008 RCT, treatment only for 3 months; no follow-up imaging
Zerwekh 2007 RCT; healthy adults with 5 weeks bed rest
RCT - randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Citrate salts versus placebo or no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Reduction in stone size 4 160 Risk Ratio (M-H, Random, 95% CI) 2.35 [1.36, 4.05]
1.1 Potassium citrate versus
no intervention or placebo
2 84 Risk Ratio (M-H, Random, 95% CI) 3.42 [1.40, 8.37]
1.2 Potassium-sodium citrate
versus no intervention or
placebo
2 76 Risk Ratio (M-H, Random, 95% CI) 1.52 [0.44, 5.21]
2 New stone formation 7 324 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.10, 0.68]
2.1 Potassium citrate versus
no intervention or placebo
3 144 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.11, 0.64]
2.2 Potassium-magnesium
citrate versus no intervention
or placebo
1 64 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.08, 0.52]
2.3 Potassium-sodium citrate
versus no intervention or
placebo
3 116 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.03, 2.63]
3 Stone size stability 4 160 Risk Ratio (M-H, Random, 95% CI) 1.97 [1.19, 3.26]
3.1 Potassium citrate versus
no intervention or placebo
2 84 Risk Ratio (M-H, Random, 95% CI) 2.19 [1.19, 4.02]
3.2 Potassium-sodium citrate
versus no intervention or
placebo
2 76 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.55, 4.51]
4 Urinary citrate levels 3 179 Mean Difference (IV, Random, 95% CI) 192.77 [108.19,
277.35]
4.1 Potassium-magnesium
citrate versus no intervention
or placebo
1 64 Mean Difference (IV, Random, 95% CI) 221.00 [84.90, 357.
10]
4.2 Potassium-sodium citrate
versus no intervention or
placebo
2 115 Mean Difference (IV, Random, 95% CI) 176.69 [42.51, 310.
86]
5 Adverse events 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Upper gastrointestinal
symptoms
4 271 Risk Ratio (M-H, Random, 95% CI) 2.55 [0.71, 9.16]
5.2 Rash 1 64 Risk Ratio (M-H, Random, 95% CI) 3.19 [0.13, 75.43]
6 Dropouts 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Non-compliance 5 311 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.72, 1.99]
6.2 Adverse events 4 271 Risk Ratio (M-H, Random, 95% CI) 4.45 [1.28, 15.50]
7 Retreatment 2 157 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.06, 0.89]
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Analysis 1.1. Comparison 1 Citrate salts versus placebo or no intervention, Outcome 1 Reduction in stone
size.
Review: Citrate salts for preventing and treating calcium containing kidney stones in adults
Comparison: 1 Citrate salts versus placebo or no intervention
Outcome: 1 Reduction in stone size
Study or subgroup Citrate Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Potassium citrate versus no intervention or placebo
Jimenez Verdejo 2001 10/25 3/25 21.1 % 3.33 [ 1.04, 10.69 ]
Soygur 2002 8/18 2/16 14.9 % 3.56 [ 0.88, 14.35 ]
Subtotal (95% CI) 43 41 35.9 % 3.42 [ 1.40, 8.37 ]
Total events: 18 (Citrate), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0070)
2 Potassium sodium citrate versus no intervention or placebo
Cicerello 1994 15/20 6/19 53.3 % 2.38 [ 1.17, 4.82 ]
Lojanapiwat 2011 3/26 2/11 10.8 % 0.63 [ 0.12, 3.29 ]
Subtotal (95% CI) 46 30 64.1 % 1.52 [ 0.44, 5.21 ]
Total events: 18 (Citrate), 8 (Control)
Heterogeneity: Tau2 = 0.46; Chi2 = 2.11, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 89 71 100.0 % 2.35 [ 1.36, 4.05 ]
Total events: 36 (Citrate), 13 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.13, df = 3 (P = 0.37); I2 =4%
Test for overall effect: Z = 3.07 (P = 0.0022)
Test for subgroup differences: Chi2 = 1.09, df = 1 (P = 0.30), I2 =8%
0.01 0.1 1 10 100
Favours control Favours citrate
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Analysis 1.2. Comparison 1 Citrate salts versus placebo or no intervention, Outcome 2 New stone
formation.
Review: Citrate salts for preventing and treating calcium containing kidney stones in adults
Comparison: 1 Citrate salts versus placebo or no intervention
Outcome: 2 New stone formation
Study or subgroup Citrate Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Potassium citrate versus no intervention or placebo
Barcelo 1993 5/18 14/20 19.0 % 0.40 [ 0.18, 0.88 ]
Jimenez Verdejo 2001 2/25 11/25 15.0 % 0.18 [ 0.04, 0.74 ]
Soygur 2002 0/28 8/28 7.7 % 0.06 [ 0.00, 0.97 ]
Subtotal (95% CI) 71 73 41.7 % 0.26 [ 0.11, 0.64 ]
Total events: 7 (Citrate), 33 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 2.69, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 2.92 (P = 0.0035)
2 Potassium-magnesium citrate versus no intervention or placebo
Ettinger 1997 4/31 21/33 18.1 % 0.20 [ 0.08, 0.52 ]
Subtotal (95% CI) 31 33 18.1 % 0.20 [ 0.08, 0.52 ]
Total events: 4 (Citrate), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.29 (P = 0.0010)
3 Potassium sodium citrate versus no intervention or placebo
Cicerello 1994 0/20 6/19 7.6 % 0.07 [ 0.00, 1.22 ]
Hofbauer 1994 11/16 16/22 21.0 % 0.95 [ 0.62, 1.44 ]
Lojanapiwat 2011 1/13 11/26 11.6 % 0.18 [ 0.03, 1.26 ]
Subtotal (95% CI) 49 67 40.3 % 0.29 [ 0.03, 2.63 ]
Total events: 12 (Citrate), 33 (Control)
Heterogeneity: Tau2 = 2.94; Chi2 = 10.44, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 151 173 100.0 % 0.26 [ 0.10, 0.68 ]
Total events: 23 (Citrate), 87 (Control)
Heterogeneity: Tau2 = 1.10; Chi2 = 29.40, df = 6 (P = 0.00005); I2 =80%
Test for overall effect: Z = 2.74 (P = 0.0062)
Test for subgroup differences: Chi2 = 0.18, df = 2 (P = 0.91), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
More with control More with citrate
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Analysis 1.3. Comparison 1 Citrate salts versus placebo or no intervention, Outcome 3 Stone size stability.
Review: Citrate salts for preventing and treating calcium containing kidney stones in adults
Comparison: 1 Citrate salts versus placebo or no intervention
Outcome: 3 Stone size stability
Study or subgroup Citrate Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Potassium citrate versus no intervention or placebo
Jimenez Verdejo 2001 13/25 6/25 40.3 % 2.17 [ 0.98, 4.79 ]
Soygur 2002 10/18 4/16 28.4 % 2.22 [ 0.86, 5.71 ]
Subtotal (95% CI) 43 41 68.7 % 2.19 [ 1.19, 4.02 ]
Total events: 23 (Citrate), 10 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.011)
2 Potassium sodium citrate versus no intervention or placebo
Cicerello 1994 4/20 4/19 16.6 % 0.95 [ 0.28, 3.27 ]
Lojanapiwat 2011 13/26 2/11 14.7 % 2.75 [ 0.74, 10.20 ]
Subtotal (95% CI) 46 30 31.3 % 1.58 [ 0.55, 4.51 ]
Total events: 17 (Citrate), 6 (Control)
Heterogeneity: Tau2 = 0.15; Chi2 = 1.36, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 0.85 (P = 0.39)
Total (95% CI) 89 71 100.0 % 1.97 [ 1.19, 3.26 ]
Total events: 40 (Citrate), 16 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.71, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0082)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours citrate
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Analysis 1.4. Comparison 1 Citrate salts versus placebo or no intervention, Outcome 4 Urinary citrate
levels.
Review: Citrate salts for preventing and treating calcium containing kidney stones in adults
Comparison: 1 Citrate salts versus placebo or no intervention
Outcome: 4 Urinary citrate levels
Study or subgroup Citrate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mg/d] N Mean(SD)[mg/d] IV,Random,95% CI IV,Random,95% CI
1 Potassium-magnesium citrate versus no intervention or placebo
Ettinger 1997 31 769 (289) 33 548 (265) 25.6 % 221.00 [ 84.90, 357.10 ]
Subtotal (95% CI) 31 33 25.6 % 221.00 [ 84.90, 357.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
2 Potassium sodium citrate versus no intervention or placebo
Cicerello 1994 20 647.6 (91.2) 19 409.8 (157.1) 44.8 % 237.80 [ 156.64, 318.96 ]
Lojanapiwat 2011 39 405.3 (305.44) 37 305.3 (233.08) 29.6 % 100.00 [ -21.78, 221.78 ]
Subtotal (95% CI) 59 56 74.4 % 176.69 [ 42.51, 310.86 ]
Heterogeneity: Tau2 = 6706.79; Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 2.58 (P = 0.0099)
Total (95% CI) 90 89 100.0 % 192.77 [ 108.19, 277.35 ]
Heterogeneity: Tau2 = 2440.72; Chi2 = 3.51, df = 2 (P = 0.17); I2 =43%
Test for overall effect: Z = 4.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
-500 -250 0 250 500
Higher with control Higher with citrate
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Analysis 1.5. Comparison 1 Citrate salts versus placebo or no intervention, Outcome 5 Adverse events.
Review: Citrate salts for preventing and treating calcium containing kidney stones in adults
Comparison: 1 Citrate salts versus placebo or no intervention
Outcome: 5 Adverse events
Study or subgroup Citrate Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Upper gastrointestinal symptoms
Barcelo 1993 5/28 1/29 22.4 % 5.18 [ 0.64, 41.59 ]
Ettinger 1997 13/31 13/33 49.5 % 1.06 [ 0.59, 1.92 ]
Hofbauer 1994 4/25 0/25 14.6 % 9.00 [ 0.51, 158.85 ]
Jimenez Verdejo 2001 2/50 0/50 13.6 % 5.00 [ 0.25, 101.58 ]
Subtotal (95% CI) 134 137 100.0 % 2.55 [ 0.71, 9.16 ]
Total events: 24 (Citrate), 14 (Control)
Heterogeneity: Tau2 = 0.77; Chi2 = 5.46, df = 3 (P = 0.14); I2 =45%
Test for overall effect: Z = 1.44 (P = 0.15)
2 Rash
Ettinger 1997 1/31 0/33 100.0 % 3.19 [ 0.13, 75.43 ]
Subtotal (95% CI) 31 33 100.0 % 3.19 [ 0.13, 75.43 ]
Total events: 1 (Citrate), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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More with control More with citrate
34Citrate salts for preventing and treating calcium containing kidney stones in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 Citrate salts versus placebo or no intervention, Outcome 6 Dropouts.
Review: Citrate salts for preventing and treating calcium containing kidney stones in adults
Comparison: 1 Citrate salts versus placebo or no intervention
Outcome: 6 Dropouts
Study or subgroup Citrate Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-compliance
Barcelo 1993 8/28 8/29 37.2 % 1.04 [ 0.45, 2.38 ]
Cicerello 1994 0/20 1/20 2.6 % 0.33 [ 0.01, 7.72 ]
Ettinger 1997 10/31 7/33 37.1 % 1.52 [ 0.66, 3.50 ]
Hofbauer 1994 5/25 3/25 14.7 % 1.67 [ 0.45, 6.24 ]
Jimenez Verdejo 2001 2/50 3/50 8.4 % 0.67 [ 0.12, 3.82 ]
Subtotal (95% CI) 154 157 100.0 % 1.20 [ 0.72, 1.99 ]
Total events: 25 (Citrate), 22 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.75, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
2 Adverse events
Barcelo 1993 2/28 1/29 28.3 % 2.07 [ 0.20, 21.58 ]
Ettinger 1997 5/31 1/33 35.6 % 5.32 [ 0.66, 43.05 ]
Hofbauer 1994 4/25 0/25 18.9 % 9.00 [ 0.51, 158.85 ]
Jimenez Verdejo 2001 2/50 0/50 17.2 % 5.00 [ 0.25, 101.58 ]
Subtotal (95% CI) 134 137 100.0 % 4.45 [ 1.28, 15.50 ]
Total events: 13 (Citrate), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 3.65, df = 1 (P = 0.06), I2 =73%
0.005 0.1 1 10 200
Less with citrate Less with control
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Analysis 1.7. Comparison 1 Citrate salts versus placebo or no intervention, Outcome 7 Retreatment.
Review: Citrate salts for preventing and treating calcium containing kidney stones in adults
Comparison: 1 Citrate salts versus placebo or no intervention
Outcome: 7 Retreatment
Study or subgroup Citrate Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Barcelo 1993 1/28 12/29 34.1 % 0.09 [ 0.01, 0.62 ]
Jimenez Verdejo 2001 4/50 11/50 65.9 % 0.36 [ 0.12, 1.07 ]
Total (95% CI) 78 79 100.0 % 0.22 [ 0.06, 0.89 ]
Total events: 5 (Citrate), 23 (Control)
Heterogeneity: Tau2 = 0.46; Chi2 = 1.70, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with citrate Less with control
A D D I T I O N A L T A B L E S
Table 1. Adverse events
Study Dropouts due to non-
compliance
Dropouts due to ad-
verse events
Side effects Re-treatment
Barcelo 1993 Treatment: 8
Control: 8
Treatment: GI symptoms
(2)
Control: GI symptoms
(1)
Treatment: minor GI
symptoms (3)
Control: no events
Treatment: ESWL (1)
Control: ESWL (10),
basket removal (1), open
removal (1)
Cicerello 1994 Treatment: 0
Control: 0
Not reported Not reported Not reported
Ettinger 1997 Treatment: 10
Control: 7
Treatment: gas/bloat-
ing/nausea (3), difficulty
swallowing (1), skin rash
(1)
Control: difficulty swal-
lowing (1)
11% of all subjects had
difficulty swallowing; 41.
9% citrate and 39.4%
control had new or wors-
ening GI symptoms; 11.
5% citrate had diarrhoea
(one patient reported
multiple episodes)
Not reported
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Table 1. Adverse events (Continued)
Hofbauer 1994 Treatment: 5
Control: 3
Treatment: GI symptoms
(4)
Control: 0
Treatment:
stomach pain, mild diar-
rhoea, nausea (4)
Control: no events
Not reported
Jimenez Verdejo 2001 Treatment: 2
Control: 3
Treatment: GI symptoms
(2)
Control: 0
Not reported Treatment: ESWL (4)
Control: ESWL (11)
Lojanapiwat 2011 4 (group not reported) Not reported Not reported Not reported
Soygur 2002 14 (group not reported) Epigastric discomfort (6)
(group not reported)
Not reported Not reported
ESWL - extracorporeal shock wave lithotripsy; GI - gastrointestinal
A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. MeSH descriptor Citrates explode all trees
2. ((potassium or sodium or calcium) and citrate*):ti,ab,kw in Clinical Trials
3. (isocitrate*):ti,ab,kw in Clinical Trials
4. (citric acid*):ti,ab,kw in Clinical Trials
5. (1 OR 2 OR 3 OR 4)
6. MeSH descriptor Urolithiasis explode all trees
7. (nephrolithiasis* or urolithiasis* or lithiasis*):ti,ab,kw in Clinical Trials
8. ((stone* or calcul*) and (renal or kidney* or urin* or ureter*)):ti,ab,kw in Clinical Trials
9. (6 OR 7 OR 8)
10. (5 AND 9)
MEDLINE 1. exp Citrates/
2. ((potassium or sodium or calcium) and citrate$).tw.
3. isocitrate$.tw.
4. citric acid$.tw.
5. or/1-4
6. exp Urolithiasis/
7. nephrolithiasis.tw.or urolithiasis.tw or lithiasis.tw
8. ((stone$ or calcul$) and (renal or kidney$ or urin$ or ureter*)).tw
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(Continued)
9. or/6-8
10. and/5,9
EMBASE 1. citric acid/
2. ((potassium or sodium or calcium) and citrate$).tw.
3. isocitrate$.tw.
4. citric acid$.tw.
5. or/1-4
6. exp Urolithiasis/
7. nephrolithiasis.tw. or urolithiasis.tw or lithiasis.tw
8. ((stone$ or calcul$) and (renal or kidney$ or urin$ or ureter*)).tw.
9. or/6-8
10. and/5,9
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
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(Continued)
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
39Citrate salts for preventing and treating calcium containing kidney stones in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Calcium Oxalate; Calcium Phosphates; Citrates [adverse effects; ∗therapeutic use; urine]; Drug Combinations; Kidney Calculi
[∗chemistry; prevention & control; ∗therapy]; Magnesium Compounds [therapeutic use]; Potassium Compounds [therapeutic use];
Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention
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MeSH check words
Adult; Humans
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